Industry Day 2026

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

At Gilead, we set – and achieve – bold ambitions to create a healthier world for all people. From our pioneering virology medicines to our growing impact in oncology, we’re delivering innovations once thought impossible in medicine. Our focus goes beyond medicines, and we also strive to remedy health inequities and break down barriers to care. We empower our people to tackle these challenges, and we’re all united in our commitment to help millions of people live healthier lives.

The Gill Corporation is a leading manufacturer of high performance composite materials and products for the aerospace, transportation and other industries. Products include honeycomb, sandwich panels, cargo compartment liners, specialty laminates, 3-, 5-, 6-axis CNC machined parts, fabricated assemblies, and other value add solutions. Four vertically integrated worldwide locations in Maryland, France, United Kingdom and headquartered in El Monte, CA USA.

Hyundai Motor Company has risen as a globally recognized automobile manufacturer that exports its branded vehicles to over 200 countries. It is equipped with production bases all around the world. It is expanding the automobile market through its success in mass-producing hydrogen-powered vehicles for the first time in the world and launching GENESIS, a high-end brand, while propelling the future mobility industry forward based on its leadership in autonomous driving and connectivity technologies. It seeks to find better solutions for humanity by achieving technological innovation under the aim of “Progress for Humanity”.

IBM Quantum leads the world in quantum computing, a technology we believe will power the next step in computing as a whole. In 2016, we made history by putting the first quantum processor in the cloud, enabling anyone to run experiments on quantum hardware. Since then, not only have we built the world’s largest quantum computing community—with more than 400,000 users exploring this nascent technology through IBM Quantum cloud services and tools like Qiskit Runtime—but we’ve also established the world’s largest quantum workforce. Now, with a quantum fleet comprising 20+ of the world’s most powerful quantum systems, IBM Quantum aims to transform society’s most challenging problems into valuable opportunities. As part of our work toward that goal, we are committed to fostering a truly global quantum economy.

Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world’s most significant health challenges. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: “Take what you find here and make it better and better.”

But we’re not only dedicated to making medicines. We go beyond medicine to deliver innovative clinical trials that reflect the diversity of our world and work to ensure our medicines are accessible and affordable.

For more than a century, Novo Nordisk has translated unmet medical needs into innovative medicines and delivery systems, like insulin pens, and today continue to reimagine what’s possible through bold science.

From labs to factory floors, Novo Nordisk is discovering and developing innovative biological medicines and making them accessible to people living with diabetes, obesity, and rare blood and endocrine diseases around the world.

Telesis Bio is transforming how the world builds biology. Our flagship Gibson SOLA® platform enables on-demand, high-fidelity DNA and mRNA synthesis directly within customer labs—eliminating delays and constraints from traditional outsourcing. By combining enzymatic synthesis chemistry with standard laboratory automation and intuitive design software, Gibson SOLA gives scientists full control over their build timelines, data, and discovery pipelines.

Researchers around the globe—from top-tier biopharma to emerging biotech startups—are using Telesis Bio’s technology to accelerate breakthroughs in vaccine development, precision immunotherapy, antibody engineering, and sustainable bio-based products. We’re proud to power synthetic biology innovation at scale—faster, cleaner, and more securely than ever before.